SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Dimebon(TM), its lead product candidate, in Alzheimer's disease.
Rachelle Doody, M.D., Ph.D., lead investigator for the study, will present the 12-month results for the first time at a scientific meeting at the 2007 Alzheimer's Association International Conference on Prevention of Dementia in Washington, D.C. Dr. Doody will present the data (abstract #S3-02-03, "Results of a One-Year Randomized, Placebo-Controlled Trial of Dimebon for the Treatment of Mild to Moderate Alzheimer's Disease") on Tuesday, June 12, at 10:00 a.m. Eastern time during the symposium session on "Emerging Compounds." Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.
The Alzheimer's Association, sponsor of the Prevention of Dementia conference, has selected the Dimebon data for inclusion in a news briefing to be held during the conference. That news briefing, which will focus on Alzheimer's disease therapies and be open to credentialed reporters, writers or editors from recognized external print, broadcast, syndicated or online news organizations, will take place at 12:00 p.m. Eastern time on Monday, June 11.
To participate in the live call on Monday, June 11, at 8:30 a.m. Eastern time by telephone, please dial 800-565-5442 from the U.S. or 913-312-1298 internationally. A telephone replay will be available for seven days following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4782383. Individuals interested in listening to the l ive call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470 x201; or Jani Bergan of W eissComm Partners, +1-415-946-1064
Web site: http://www.medivation.com/
Ticker Symbol: (NASDAQ-NMS:MDVN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company